Latest Breaking News On - ராஜீவ் வெண்கய்யா - Page 8 : vimarsana.com

Takeda and IDT Support Manufacturing of Johnson & Johnson’s COVID-19 Vaccine Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced a mutual agreement with IDT Biologika GmbH (“IDT”), a contract development and manufacturing organization, to utilize capacity at IDT previously reserved for Takeda’s dengue vaccine candidate (TAK-003) to manufacture the single-shot COVID-19 vaccine developed by the Janssen Pharmaceutical Companies of Johnson & Johnson. At the end of a three-month period, the capacity will be returned to Takeda to resume critical manufacturing for the planned launch of its dengue vaccine, subject to regulatory approvals. “We are pleased to work with IDT to support Janssen’s efforts to make its COVID-19 vaccine available and accessible to as much of the world as possible,” said Rajeev Venkayya, President, Global Vaccine Business Unit at Takeda. “We also recognize the massive unmet need for a dengue vaccine and will work

United statesBiologika gmbRajeev venkayyaPlasma allianceTakeda pharmaceutical company limitedGerman centerJanssen pharmaceutical companies of johnsonCare allianceTakeda pharmaceutical companyExchange commissionCovid rd allianceGovernment of japan ministry health labourVaccine researchJanssen pharmaceutical companiesGlobal vaccine business unitHealth labour